Half-Year 2022 Financial and Clinical Trials Update

Major pending approvals 2022 RG6152 US Xofluza influenza pediatric Filed March 2020 Lunsumio (mosunetuzumab) EU Susvimo (PDS) China Rozlytrek RG6321 WAMD Filed April 2021 Vabysmo (faricimab) RG6268 ROS1+ NSCLC Filed Oct 2021 Rozlytrek RG7596 Japan-Chugai Polivy 1L DLBCL Filed Dec 2021 Gazyva RG7828 3L+ FL RG7716 Filed Dec 2021 Actemra DME Filed May 2021 Vabysmo (faricimab) RG6268 NTRK+ solid tumors Filed Nov 2021 RG7159 1L CLL Filed March 2022 RG1569 COVID-19 pneumonia Filed Jan 2022 RG7716 WAMD RG7596 Filed May 2021 Hemlibra RG6013 mild to moderate hemophilia A RG7596 Filed Oct 2021 Polivy 1L DLBCL Filed Nov 2021 Polivy r/r DLBCL Filed Dec 2021 RG6396 RG6152 RG7916 RG6413+ RG6412 RG6026 Status as of July 21, 2022 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Gavreto RET+ MTC, TC Filed Nov 2021 Xofluza influenza pediatric Filed Nov 2021 Evrysdi SMA presymptomatic pediatric <2mo Filed Nov 2021 Ronapreve** SARS-CoV-2 hospitalized Filed Jan 2022 glofitamab 3L+ DLBCL Filed April 2022 Metabolism Neuroscience Ophthalmology Other Roche PDS-Port Delivery System with ranibizumab **Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals 78

View entire presentation